Literature DB >> 16601093

Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population.

G A Tramper-Stranders1, C K van der Ent, M G Slieker, S W J Terheggen-Lagro, F Teding van Berkhout, J L L Kimpen, T F W Wolfs.   

Abstract

BACKGROUND: Serological methods to monitor Pseudomonas aeruginosa colonisation in patients with cystic fibrosis (CF) are advocated but the diagnostic value of a commercially available P aeruginosa antibody test to detect early and chronic P aeruginosa colonisation in a non-research setting has not been assessed.
METHODS: Colonisation with P aeruginosa was estimated by regular culture of sputum or oropharyngeal swabs during three consecutive years in 220 patients with CF aged 0-65 years. Commercially available ELISA tests with three P aeruginosa antigens (elastase, exotoxin A, alkaline protease) were performed at the end of the study period. In a subgroup of 57 patients (aged 4-14 years) serological tests were performed annually.
RESULTS: Using culture as the reference standard, the ELISA tests using the advised cut off values had a sensitivity of 79% and a specificity of 89% for chronic colonisation. Receiver-operator characteristic curves were created to optimise cut off values. Applying these new cut off values resulted in a sensitivity of 96% and a specificity of 79%. All three individual serological tests discriminated well between the absence and presence of chronic P aeruginosa colonisation. The sensitivity of the individual antibody test was 87% for elastase, 79% for exotoxin A, and 76% for alkaline protease. First colonisation was preceded by positive serological results in only five of 13 patients (38%).
CONCLUSION: In patients with CF, serological tests using specific antigens are sensitive for diagnosing chronic P aeruginosa colonisation. However, the failure of serological tests to detect early colonisation in young patients emphasises the need for continued reliance on cultures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601093      PMCID: PMC2104678          DOI: 10.1136/thx.2005.054726

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Maintenance treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  N Høiby; C Koch
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

Review 2.  A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis.

Authors:  Joachim E Fischer; Lucas M Bachmann; Roman Jaeschke
Journal:  Intensive Care Med       Date:  2003-05-07       Impact factor: 17.440

3.  Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.

Authors:  M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener
Journal:  Pediatr Pulmonol       Date:  1999-11

4.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.

Authors:  J L Burns; R L Gibson; S McNamara; D Yim; J Emerson; M Rosenfeld; P Hiatt; K McCoy; R Castile; A L Smith; B W Ramsey
Journal:  J Infect Dis       Date:  2000-12-27       Impact factor: 5.226

5.  Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.

Authors:  M R Kosorok; L Zeng; S E West; M J Rock; M L Splaingard; A Laxova; C G Green; J Collins; P M Farrell
Journal:  Pediatr Pulmonol       Date:  2001-10

6.  Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

Authors:  F Ratjen; G Döring; W H Nikolaizik
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 7.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

8.  Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.

Authors:  Helle Krogh Johansen; Lena Nørregaard; Peter C Gøtzsche; Tacjana Pressler; Christian Koch; Niels Høiby
Journal:  Pediatr Pulmonol       Date:  2004-05

9.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

10.  Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.

Authors:  Susan E H West; Lan Zeng; Bee Leng Lee; Michael R Kosorok; Anita Laxova; Michael J Rock; Mark J Splaingard; Philip M Farrell
Journal:  JAMA       Date:  2002-06-12       Impact factor: 157.335

View more
  7 in total

1.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

2.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

3.  Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.

Authors:  D Hayes; P M Farrell; Z Li; S E West
Journal:  Pediatr Pulmonol       Date:  2010-01

Review 4.  Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.

Authors:  Luiz Vicente Ribeiro Ferreira da Silva Filho; Flavia de Aguiar Ferreira; Francisco José Caldeira Reis; Murilo Carlos Amorim de Britto; Carlos Emilio Levy; Otavio Clark; José Dirceu Ribeiro
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

5.  Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA).

Authors:  Renan Marrichi Mauch; Cláudio Lúcio Rossi; José Dirceu Ribeiro; Antônio Fernando Ribeiro; Marcos Tadeu Nolasco da Silva; Carlos Emílio Levy
Journal:  Diagn Pathol       Date:  2014-08-22       Impact factor: 2.644

6.  Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.

Authors:  Henrique Douglas M Coutinho; Vivyanne S Falcão-Silva; Gregório Fernandes Gonçalves
Journal:  Int Arch Med       Date:  2008-11-07

7.  Immunoproteomic Profiling of Antiviral Antibodies in New-Onset Type 1 Diabetes Using Protein Arrays.

Authors:  Xiaofang Bian; Garrick Wallstrom; Amy Davis; Jie Wang; Jin Park; Andrea Throop; Jason Steel; Xiaobo Yu; Clive Wasserfall; Desmond Schatz; Mark Atkinson; Ji Qiu; Joshua LaBaer
Journal:  Diabetes       Date:  2015-10-08       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.